Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8137308 | 0.91 | MEN1 (0.55) | CTSDCTSKCTSLCTSBCTSS | |
| SCHEMBL29861422 | 0.90 | CTSB (0.61) | CTSDCTSKCTSLCTSBCTSS | |
| SCHEMBL29973490 | 0.90 | MMP1 (0.51) | CTSKCTSLCTSBCTSSTACR1 | |
| SCHEMBL13392171 | 0.89 | CTSK (0.57) | CTSDCTSKCTSLCTSBCTSS | |
| SCHEMBL1509254 | 0.89 | CTSK (0.57) | CTSKCTSLCTSBCTSSTACR1 | |
| SCHEMBL9416814 | 0.89 | ALDH1A1 (0.62) | CTSDCTSKCTSLCTSBCTSS | |
| SCHEMBL9219338 | 0.88 | CTSK (0.62) | CTSKCTSLCTSBCTSSTACR1 | |
| SCHEMBL19485480 | 0.88 | CTSK (0.62) | CTSKCTSLCTSBCTSSTACR1 | |
| SCHEMBL25908075 | 0.87 | SYK (0.57) | CTSDCTSKCTSLCTSBCTSS | |
| SCHEMBL8612027 | 0.87 | CTSS (0.54) | CTSDCTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4083051-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-114867734-A | Method for synthesizing peptide compound | 中外制药株式会社 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | VIP, NGLY1, NPPA | CTSD 194/4885CTSK 214/4885CTSL 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.